Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency.
Pfeuffer S; Pawlowski M; Joos GS; Minnerup J; Meuth SG; Dziewas R; Wiendl H
Research article (journal) | Peer reviewedAbstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 can result in severe disease and become critically challenging to hospitals via high demand for intensive care and mechanical ventilation. Guillain-Barré syndrome (GBS) and its variants have been described as neurologic complications of COVID-19, and fatal cases were reported.1 The mechanisms by which COVID-19 predisposes to autoimmunity are unclear, and potential biomarkers or risk factors remain unknown.
Details about the publication
Journal: Neurology: Neuroimmunology and NeuroInflammation (Neurol Neuroimmunol Neuroinflamm)
Volume: 7
Issue: 6
Status: Published
Release year: 2020 (28/11/2020)
Language in which the publication is written: English
Link to the full text: https://www.neurology.org/doi/10.1212/NXI.0000000000000881?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Keywords: Adult; Autoimmunity; Betacoronavirus; COVID-19; Coronavirus Infections; Female; Humans; IgA Deficiency; Pandemics; Plasma Exchange; Pneumonia, Viral; SARS-CoV-2
Authors from the University of Münster
| Dziewas, Rainer | Department for Neurology |
| Joos, Gunther | Clinic for Anaesthesiology, Surgical Critical Care Medicine and Pain Therapy |
| Minnerup, Jens | Department for Neurology |
| Pawlowski, Matthias | Department for Neurology |
| Wiendl, Heinz Siegfried | Department for Neurology |